DelveInsight Report Analyzes Idiopathic Pulmonary Fibrosis Drug Development
DelveInsight has released a new report analyzing the status of over 70 companies and 75 drug development programs for Idiopathic Pulmonary Fibrosis through 2026.
Market research firm DelveInsight has published a comprehensive analysis of the current state and future prospects of drug development for Idiopathic Pulmonary Fibrosis (IPF) up to 2026.
The report, "Idiopathic Pulmonary Fibrosis Pipeline Insight, 2026," details the progress of over 70 companies and 75 drug candidates in the pipeline. It covers drugs in both clinical and non-clinical stages, evaluating them by type, stage, route of administration, and molecule type. The analysis also identifies inactive pipeline products.
IPF is a rare, chronic, and progressive lung disease characterized by scarring and stiffening of lung tissue, leading to reduced oxygen intake. Symptoms include shortness of breath and cough. The exact cause is often unknown, and diagnosis relies on clinical, radiological, and sometimes biopsy data.
According to DelveInsight's analysis, drug development efforts are focused on novel approaches targeting the disease's underlying pathogenic pathways. The report provides detailed insights into the mechanism of action, clinical studies, and development activities of pipeline candidates, including collaborations and licensing agreements.
Among the emerging drugs highlighted is Bristol-Myers Squibb's Admilparant (BMS-986278), an oral, small molecule lysophosphatidic acid receptor 1 (LPA1) antagonist being investigated as a potential antifibrotic treatment for IPF.